A Korean study compared 80 men, half aged 20‑30 and the other half 45‑55, to see how age and physical activity affect muscles and the nervous system. Both groups exercised at similar levels, yet the older participants had higher body fat and showed signs of neuromuscular decline. Specifically, neurofilament light chain (NfL), a marker of neurodegeneration, was higher in middle‑aged men, while lower‑leg muscle function—measured by knee peak torque and rate of torque development—was reduced. Moreover, the C‑terminal agrin fragment (CAF), indicating neuromuscular junction degradation, was lower in those with higher activity levels. These findings suggest muscle and neuromuscular deterioration can start already in middle age, but regular exercise may slow the process. The authors recommend tailored exercise programs to preserve muscle health and nerve connections, preventing early loss of strength and mobility.
The study assessed muscle function using isokinetic dynamometry, measuring knee extension peak torque and torque normalized to body weight (BW/PT). Additionally, the rate of torque development (RTD) at 0.18 s was calculated, a sensitive indicator of rapid force generation crucial for daily tasks like climbing stairs. The biomarkers analyzed include neurofilament light chain (NfL), a structural axonal protein released into the blood upon neuronal damage, and the C‑terminal agrin fragment (CAF), produced by agrin degradation, a key protein for neuromuscular junction (NMJ) stability. Elevated NfL in middle‑aged subjects suggests subclinical neurodegeneration, while lower CAF in more active individuals indicates reduced NMJ degradation. These data support the hypothesis that physical activity can modulate neuromuscular aging processes, likely via neuroplasticity mechanisms and maintenance of NMJ protein synthesis. The interaction between mechanical factors (exercise) and molecular markers (biomarkers) paves the way for targeted interventions, such as high‑velocity resistance programs, to preserve rapid force generation capacity and mitigate early sarcopenia risk. Moreover, circulating biomarker assessment provides a non‑invasive window to monitor NMJ status and adapt interventions in real time, promoting preventive medicine based on individual biological data.
